CTOs on the Move

Crucell Biologics

www.crucell.com

 
Crucell N.V. (Crucell) is a biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. Crucell product candidates include flu-mAb, an antibody product effective against a range of
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.crucell.com
  • 4216 Ponce De Leon Blvd
    Miami, FL USA 33146
  • Phone: 800.533.5899

Executives

Name Title Contact Details

Similar Companies

Physician Partner

Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cadila Pharmaceuticals - CPL

Cadila Pharmaceuticals - CPL, Inc. is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MacroCap Labs

MacroCap Labs is a contract manufacturing company founded in 2010. With steady improvements in quality and capacity, we have become one of the top contract manufacturers in the state of Florida. Our FDA registered facility ensures that we meet or excee...

Abivax

Abivax is a clinical stage biopharmaceutical company that focuses on developing treatments for inflammatory diseases, viral infections, and cancer by modulating the bodys natural immune system machinery.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.